Towards Understanding the Gene-Specific Roles of GATA Factors in Heart Development: Does GATA4 Lead the Way?

Boni A. Afouda

Institute of Medical Sciences, Foresterhill Health Campus, University of Aberdeen, Aberdeen AB25 2ZD, Scotland, UK; boni.afouda@abdn.ac.uk; Tel.: +44-1224-437490; Fax: +44-1224-437465

Abstract: Transcription factors play crucial roles in the regulation of heart induction, formation, growth and morphogenesis. Zinc finger GATA transcription factors are among the critical regulators of these processes. GATA4, 5 and 6 genes are expressed in a partially overlapping manner in developing hearts, and GATA4 and 6 continue their expression in adult cardiac myocytes. Using different experimental models, GATA4, 5 and 6 were shown to work together not only to ensure specification of cardiac cells but also during subsequent heart development. The complex involvement of these related gene family members in those processes is demonstrated through the redundancy among them and crossregulation of each other. Our recent identification at the genome-wide level of genes specifically regulated by each of the three family members and our earlier discovery that gata4 and gata6 function upstream, while gata5 functions downstream of noncanonical Wnt signalling during cardiac differentiation, clearly demonstrate the functional differences among the cardiogenic GATA factors. Such suspected functional differences are worth exploring more widely. It appears that in the past few years, significant advances have indeed been made in providing a deeper understanding of the mechanisms by which each of these molecules function during heart development. In this review, I will therefore discuss current evidence of the role of individual cardiogenic GATA factors in the process of heart development and emphasize the emerging central role of GATA4.

Keywords: transcription factors; heart development; GATA4 genes; noncanonical Wnt signalling

1. Introduction

Cardiovascular-related disease is a leading cause of death worldwide, and the prevalence of congenital heart defects is around 1% of live births, with up to 10% of spontaneously aborted foetuses found to be affected by cardiovascular diseases [1,2]. Thus, intense efforts have been made over the past few years to improve our understanding of the mechanisms underlying heart formation by characterising the molecular mechanisms involved. Amongst the first genes expressed during heart specification are those encoding a family of highly conserved zinc finger transcription factors named GATA factors [3] that have also been shown to be involved in the development of hematopoietic [4], digestive and reproductive systems [5]. Six paralogs were identified in vertebrates and originally divided fundamentally into a hematopoietic (GATA1/2/3) and a cardiac (GATA4/5/6) subfamily. The three cardiogenic GATA factors are known to be important and required for heart development as I discuss below (see Table 1 and Section 1). These three “sisters” (GATA4, 5 and 6) have also been shown to be (to some extent) sufficient for promoting different aspects of heart development as their overexpression leads to the induction of cardiac differentiation. For instance, forced expression of Gata4 enhances cardiogenesis during Xenopus embryogenesis [6] or in P19 embryonal carcinoma cells [7]. In addition, Gata4 expression in stem cell-like embryonic explants was shown to be sufficient to induce cardiac differentiation of cardiomyocytes [8–11]. Studies using an engineered embryonic stem cell (ESC) line that allow conditional expression of Gata5 show that the expression of that single factor (and its sisters Gata4 and 6 under defined culture conditions) is sufficient to
promote abundant populations of beating and phenotypically normal cardiac cells [12]. Furthermore, although GATA4, 5 and 6 have all been shown to be implicated in heart formation, evidence about their specific roles in that process differs depending on the species in which the investigations were carried out. The apparent confusing picture that has then appeared due to these differences among species, makes identification of specific functions of specific cardiogenic GATA genes difficult to dissect.

Table 1. The importance of Gata4, 5 and 6 in heart formation. Biological functions and cardiac defects associated in humans and mice.

| GATA Factors | Cardiac Defects Associated with Human Mutations | Mouse Phenotypes | Cardiac Expression | Biological Functions |
|--------------|-----------------------------------------------|------------------|--------------------|----------------------|
| GATA6 / Gata6 | -Atrial septal defects -Atrioventricular septal defects -Bicuspid aortic valves -Dilated cardiomyopathy -Double outlet left ventricle -Double outlet right ventricle -Tetralogy of Fallot -Ventricular septal defects | Embryonic lethal at E5.5–E7 | Yes | -Cardiac hypertrophy [13] -Cardiac morphogenesis [14] -Outflow tract development [15–18] |
| GATA5 / Gata5 | -Atrial septal defects -Atrioventricular septal defects -Bicuspid aortic valves -Dilated cardiomyopathy -Double outlet right ventricle -Hypertrophic cardiomyopathy -Tetralogy of Fallot -Ventricular septal defects | Viable and fertile | Yes | -Endocardial cell development [19] -Vascular endothelial homeostasis [20] |
| GATA4 / Gata4 | -Atrial septal defects -Atrioventricular septal defects -Bicuspid aortic valves -Double inlet left ventricle -Double outlet right ventricle -Hypertrophic cardiomyopathy -Tetralogy of Fallot -Ventricular septal defects | Embryonic lethal at E9.5 | Yes | -Cardiomyocyte proliferation, differentiation and hypertrophy [13] -Endocardial cell proliferation [21] -Heart tube formation and ventral morphogenesis [22,23] |

In our own research, in order to understand the specific function of individual cardiogenic gata during heart development, we profiled gene expression at a genome-wide level in settings where they were either individually depleted or depleted in combination and compared these to those in normal cardiac tissues [24,25] (Figure 1B). We were able to firstly identify genes specifically regulated by individual GATA factors during heart development in Xenopus laevis and secondly confirm that some are conserved in mammals. We also uncovered some functionally distinct roles for gata4, 5 and 6 during heart formation using the experimentally accessible Xenopus model. Wnt signalling pathways are involved in the processes that drive cardiac fate and development. Using antisense morpholino oligonucleotides to block the function of gata4, 5 and 6, we showed that the loss of gata4 and 6 results in the inhibition of both early and late cardiogenic markers, while the loss of gata5 leads only to the inhibition of late cardiomyocyte differentiation markers [11] (Figure 1A). We demonstrated that while the effects resulting from the loss of gata4 and 6 functions can be rescued by activating noncanonical Wnt11b signalling, the loss of gata5 function cannot be rescued by noncanonical Wnt signalling, suggesting therefore that the differential requirements for GATA factors during cardiac differentiation are mediated by noncanonical Wnt11b signalling [11].
Another level of complexity in the functions of individual cardiogenic GATA factors in heart formation and development has emerged, firstly, from studies demonstrating redundancy [26,27] and crosstalk [28] between GATA factors during cardiogenesis (see in paragraphs below) and, secondly, from functional differences at cellular levels suggesting that some of these molecules drive cardiac fate not only cell-autonomously but also through mechanisms involving signalling molecules [9,11,28–34]. Thus, the above results obtained from a nonmammalian model system proved to be very informative and call for exploring further supportive information from mammalian model systems.

2. The Requirement of Cardiogenic Gata Genes for Heart Development

Indeed, implications of Gata6 in heart formation originally emerged from the Gata6 knockout mouse, which displayed extraembryonic endoderm defects leading to early death prior to heart induction [35,36]. It has also been shown that elevated levels of Gata6 delay the onset of maturation of cardiac precursors [37], but as I will discuss below, increased levels of Gata6 may compensate for the loss of Gata4 [14,22,23,38,39]. Studies in Xenopus [11] as well as in zebrafish have confirmed a requirement of gata6 in cardiogenesis, which, however, appears to be at the later stage of maturation (that is cardiac differentiation) rather than initial induction [30]. Further evidence has emerged from genetic studies that implicated Gata6 not only in cardiomyopathies but also in phenotypes leading to lethality [16–18,40–42].

For Gata5, in vitro studies revealed its requirement for differentiation of committed cardiogenic precursors into endocardial cells (Ecs) [19]. In zebrafish, important roles of gata5 in heart formation have been shown in studies with the gata5 (faust) mutant that lack endocardial cells resulting in a reduced number of cardiomyocytes [43]. Furthermore, targeted inactivation of Gata5 in mice [44] has shown the importance of Gata5 in the aetiology of the bicuspid aortic valve (BAV) defect during heart development [44]. In that study, the deletion of Gata5 specifically from endocardial cells was sufficient to recapitulate the cardiac phenotype of Gata5 knockout mice, suggesting a cell-autonomous function of
Gata5 in regulating endocardial cushion differentiation and the importance of that factor in mammalian heart development and congenital heart disease [45,46]. As I will discuss in more detail below, Gata4/5 compound mutant mice have been described to show more severe cardiac defects [47], and Gata4/5 and Gata5/6 compound heterozygotes present double outlet right ventricle and ventricle septal defects [15]. Although those studies highlight the importance of Gata5 in heart development, they also indicate a possible redundancy in function of GATA factors in heart formation. In that regard, studies in zebrafish and Xenopus have shown that gata5 has redundant roles with gata6 in cardiac progenitor specification [16,45,46].

With regards to GATA4, mutations in the GATA4 gene were shown to cause congenital cardiomyopathies [48–59]. However, in mice, although Gata4 knockout was shown to be embryonically lethal, its heart phenotype was shown to be secondary due to defects in the extraembryonic endoderm, with fusion at the ventral midline not occurring, associated with a cardia bifida phenotype [22,23]. Likewise, the depletion of gata4 in zebrafish has also produced morphological defects [60]. In tetraploid compensation experiments to circumvent the extraembryonic defects in Gata4-null mice, the derived embryos lacked proepicardium and showed defects in cardiac morphogenesis that included hypoplasic ventricular myocardium [61]. However, as I will discuss below, redundant roles for both Gata4 and 6 in controlling the onset of cardiac myocyte differentiation have been shown in recent studies in which double Gata4/6 KO embryos completely lack hearts, although second heart field progenitor cells are still generated [62]. In addition to its requirement for epicardial and myocardial formation, Gata4 has also been shown to be involved in endocardial cells and valve formation [63,64]. Indeed, in studies assessing the transcriptional mechanism underlying valve development in mice, Stefanovic et al. et al. have shown that Gata4 is involved in the activation and repression of atrioventricular-specific genes by acetylation and deacetylation of the atrioventricular (AV) canal gene loci [64]. This identifies GATA binding elements as a potential platform that recruit broadly active histone modification enzymes and cell-type-specific cofactors in order to drive cell-type-specific gene expression programmes. Indeed, other studies have provided evidence that the cooperation of Gata4 with active histone modification enzymes and localized cofactors ensured a proper spatiotemporal expression of cardiac genes during cardiac differentiation [65–68]. Although the above-described studies have provided a direct requirement for Gata4 in cardiomyocyte specification, in addition, gain-of-function studies suggest that Gata4 is sufficient to affect cardiomyocyte fate. For instance, forced expression of Gata4 enhances cardiogenesis during Xenopus embryogenesis [6] or in P19 embryonal carcinoma cells [7]. Furthermore, Gata4 expression in stem cell-like embryonic explants was shown to be sufficient to induce differentiation of cardiomyocytes [8–11]. Those data suggest that gata4 is a vital candidate for enhancing cardiogenesis from a progenitor cell population.

Altogether, those experiments with both those obtained based on its expression [3,5] and the phenotypes generated by various gain-and loss-of-function experiments suggest that Gata4 could be viewed as a key GATA regulator of cardiogenesis as discussed below.

The current review therefore identifies important themes emerging from recent advances made in understanding the role of cardiogenic GATA factors in heart formation with a justification to focus on Gata4.

3. Redundancy and Functional Interactions among Cardiogenic GATA Genes

Significant efforts made over the past to elucidate the molecular mechanisms involved in heart disease have identified some genes whose functions are linked to congenital heart disease (CHD) [69–71]. The emerging picture from combined human and mouse genetic studies is that mutations in different genes (such as GATA, NKX2.5 and TBX5) can lead to similar cardiac defects (polygenic), while mutations in the same gene can often lead to varying defects, for instance, in different settings (pleiotropic), suggesting a certain complexity in CHD. Such complexity for the mechanisms of CHD is also evident at both genetic and cellular levels, as multiple cell lineages contribute to proper heart formation.
Several lines of evidence confirm that CHD is heritable and that GATA4–6 are among the genes that are linked to CHDs in humans \([16–18,20,40,45,46,48,56,58,59,70,72–77]\). For example, mutations in GATA4 have been associated with atrial and/or ventricular septal defects, Tetralogy of Fallot (TOF) and persistent truncus arteriosus (PTA) \([47,48,56,78]\) (also see Table 1). Interestingly, heterozygous mutations of Gata4 in mice recapitulate the human phenotype \([49]\). However, a level of complexity regarding the involvement, functions and interactions of GATA factors in CHD have been shown in studies in which the loss of both Gata4 and Gata6 in mice leads to acardia, suggesting that genetic interactions between these factors are essential for the onset and/or maintenance of cardiogenesis \([62,78]\). In the former study, in vitro investigations using either Gata4 or Gata6 or a combined deletion of both factors in ESC, as well as embryos generated from those, confirm functional interactions between those two factors. When either Gata4 or Gata6 was disrupted, the number of beating embryoid bodies was dramatically reduced to a similar level. That observed effect for Gata4 is similar to that previously reported for the loss of Gata4 in ES embryoid bodies and may reflect a loss of extraembryonic endoderm necessary for maturation, rather than a cell-autonomous effect \([79]\). Moreover, a more penetrant effect was observed when one allele of Gata6 was disrupted in the Gata4−/− ES cells, with a complete lack of cardiac differentiation in Gata6+/−. Since no effect on cardiac progenitor status was observed, those studies confirm that Gata4 and Gata6 have some redundant functions in controlling cardiac myocyte differentiation and furthermore suggest that they are dispensable for the formation of cardiac progenitor cells. Those observed functional interactions between Gata4 and Gata6 were confirmed in the heart of embryos generated from Gata4−/− ES cells by tetraploid complementation \([79]\). Embryos with acardia or a complete lack of hearts observed from this experimental setting confirmed such functional interactions between Gata4 and Gata6 in vivo. In those studies, the absence of the heart in Gata4/6-null embryos was proven not to be a consequence of a general embryonic arrest or a defect in gastrulation, as the Gata4−/−Gata6−/− embryos did retain many features characteristic of the developmental stage E8.5 where the investigations were carried out \([62]\). Those observations are in line with previous studies in which it was shown that mice embryos with compound heterozygous mutations in Gata4 and Gata6 die at the embryonic stage around E13.5 due to several cardiac defects, among which one can cite vascular defects, PTA, evidence of failed outflow tract (OFT) septation as well as myocardial thinning, indicative of functional interaction between Gata4 and Gata6 in cardiac and vascular development \([80,81]\). Thus, those additional studies have recognised that genetic redundancy exists between Gata4 and Gata6 and that coexpression of these transcription factors characterises functional compensation \([80]\). Subsequent studies were conducted to shed light on the genetic redundancy between the GATA factor function during cardiogenesis \([27,82]\). Evidently such investigations needed to overcome the challenge of avoiding interfering in other developmental processes in which those factors are involved. Since zebrafish embryos do not rely on the equivalence of mammalian extraembryonic endoderm for early development, they provide an excellent model to generate triple gata4/5/6 knockout to probe genetic interaction among these genes. In the study by Sam et al. \([27]\), the authors generated multiple combinations of double and triple gata4/5/6 heterozygous and homozygous mutant offspring to define the individual and redundant functions of gata4/5/6 during different stages of embryonic heart development. The study not only describes individual roles of GATA factors but also describes evidence for genetic compensation and dosage requirements for gata4/5/6-dependent cardiogenesis \([27]\).

Another level of complexity in the interaction among the three cardiogenic Gata sisters has been shown in other investigations that involved Gata5. Laforest and Nemer \([15]\) investigated the genetic interaction between Gata4/Gata5 and Gata5/Gata6 in developing mice embryos. In that study, very high lethality was observed in Gata4−/−Gata5+/− double heterozygote embryos, which seems not to be due to retarded development but rather displayed defects identified as double outlet right ventricle (DORV) and ventricular septal defect (VSD) \([15]\). As both GATA4 and GATA5 are expressed in the atrioventricular cushion,
analysed embryos show that the observed defects arose from the abnormal development of endocardial cells, suggesting genetic cooperation between Gata4 and Gata5 in endocardial cushion formation. Interesting, the few Gata4+/−Gata5+− double heterozygotes that survived to adulthood presented with a massively hypertrophied aortic valve, consistent with defective valve development leading to aortic stenosis. Those data are in line with those from previous studies indicating that Gata4 and 5 cooperatively regulate cardiac myocyte proliferation in mice [47]. The study provided evidence that although Gata5−/− mice are viable, Gata4(+/−) and Gata5−/− mutants die at midgestation and exhibit profound cardiovascular defects, including abnormalities of cardiomyocyte proliferation and cardiac chamber maturation. These results demonstrate functional redundancy between Gata4 and Gata5 during cardiac development. Similar to the Gata4/Gata5 compound discussed above, genetic interaction between Gata5 and Gata6 also shows a very high embryonic or perinatal lethality as revealed in Gata5/Gata6 heterozygote compounds [15]. The aetiology of those lethalties shows the presence of DORV and VSD but interestingly only at the level of the aortic valve. The results from the above-mentioned studies clearly show an interesting and complex cooperative genetic interaction revealed in these Gata4/Gata6, Gata4/Gata5 and Gata5/Gata6 compounds, resulting in similarity with some subtle distinctions at the level of phenotypes, as well as affected molecular gene targets. Such complexity is also evident at the cellular level as multiple lineages contribute to proper heart development.

The above evidence mainly from mouse studies and to some extent zebrafish studies [27] strongly suggests that GATA factors may have redundant activities during cardiogenesis, a redundancy that is more likely as they all bind to the same binding sites with high affinity [83,84]. In addition to this, the peculiarities of the species in which the investigations were carried out make deciphering their redundancy difficult. The apparent confusing picture provided the rationale behind other investigations that aimed to improve our understanding of the redundancy function of GATA factors during cardiogenesis. This is exemplified in Peterkin et al. [26] in which the authors set out to knock down each of the cardiogenic GATA factors individually or in combination using antisense morpholinos in the experimentally accessible Xenopus and zebrafish models. In those studies, the knockdown of gata4 or gata5 individually had little effect on myocardium formation, but a clear phenotype was observed when both were knocked down together in Xenopus. In contrast, the knockdown of gata5 on its own in zebrafish had a major effect [26,43]. However, in both species, gata6 knockdown had a clear effect that was further enhanced by knocking down either gata4 or gata5 in the same embryos. This observed and more important role that gata5 plays in myocardium formation in zebrafish highlights changes in the use of the GATA factors during evolution. The relatively earlier onset of expression of Gata5 in zebrafish has been provided as a possible explanation. In other words, Gata5 is expressed in zebrafish before Nkx2.5 (a critical cardiac specifying gene), which is known to be active before GATA factors in Xenopus and in mammals. This supports the finding that these factors regulate each other in both Xenopus and zebrafish and more importantly suggests that the establishment of such mutually supportive circuits is more important than the particular order in which the two genes become active. Such a mutually supportive circuit is also observed with bone morphogenic protein (BMP), a key signalling molecule in cardiac differentiation. Interestingly, noticeable differences appear between Xenopus and zebrafish with regards to BMP signalling where nkx is active before bmp signalling in Xenopus in contrast to zebrafish where bmp signalling is active before Gata or nkx. A similar circuit is observed in invertebrates, namely Drosophila, where BMP is known as DPP [26,85], supporting the concept of some vital core regulatory circuits named kernels that operate in organogenesis during embryonic development [86].
Taken this functional redundancy into account, and as I will discuss below the mutual regulation between cardiogenic Gata genes, we can now attempt to deconvolute, distil and dissect the specific functions of GATA6, 5 and 4 in heart formation.

4. Direct and Indirect Roles of Gata6 in Cardiac Development: Is Gata6 the Junior Partner?

Mammalian Gata6-null mice die prior to heart induction at E5.5–7.5 (see Table 1) due to defects in extraembryonic endoderm [35,36] consistent with Gata6 function early in development. In mice, chimera embryo studies have shown that Gata6−/− ES cells were able to contribute to heart and differentiate into myocardium in vitro, suggesting a non-cell-autonomous role of Gata6 in heart defects. Gain-of-function studies in Xenopus, however, have suggested a role of gata6 in cardiogenesis [37]. In that study, it has been shown that proper heart development requires a decrease in expression of Gata6 in cardiac precursors, as elevating its expression beyond this time-delayed cardiomyocyte maturation. Although these findings suggest that Gata6 may hold cardiac precursor cells in a progenitor and proliferative state, further loss of function in both Xenopus and zebrafish have suggested instead that the gata6 function is required for the maturation of cardiac progenitors rather than for their initial induction [30,32]. Such function for gata6 in the developing myocardium was shown to be dependent on Bmp4 expression [29,30]. Such involvement of signalling molecules downstream of gata6, and so its cell nonautonomous function, was subsequently confirmed in Xenopus where we have shown that wnt11b mediates the differential requirements of GATA factors during cardiogenesis [11]. In that study, we identified that during the process of heart formation noncanonical Wnt signalling mediated by wnt11b functions downstream of gata6 (and gata4 but not gata5) (Figure 1A).

In humans, mutations in GATA6 have been identified in CHD highlighting its crucial role in heart formation [87] (also see Table 1). Those mutations are associated with structural and conduction system abnormalities that include valve (BAV) and septal defects [32,34,88]. In recent years, more investigations have been carried out that confirm the implication of GATA6 in OFT [16–18]. To illuminate the molecular mechanisms for those cardiovascular malformations, recent studies in human-induced pluripotent cells (hiPSCs) show that GATA6 regulates SMYD1 that activates HAND2 and that KDR with HAND2 orchestrates OFT formation [89]. Although the above-mentioned studies show GATA6’s role in CHD, GATA6, like its sister GATA4, has also been shown to be involved in postnatal cardiac regulation, for instance, in cardiac hypertrophy [41] (also see Table 1) and haemostasis. It has been shown that its hypertrophic role requires GATA6 interaction with a small heterodimer partner (a repressor) [88] and, Interestingly, with its sister GATA4 [90]. Those data suggest the importance of interacting partners and consequently post-translational modifications in Gata6 (Gata5 and Gata4 as detailed below in Sections 5 and 6) cardiac function. Among those post-translational modifications, the s290 phosphorylation [91,92] has been reported to be required for its role in vascular smooth muscle formation and its SUMOylation [93], and possibly its epigenetic modifications are involved for its role in heart development such as for its sister Gata4 [66] (as discussed below).

A further level of complexity regarding the function of Gata6 has been revealed in subsequent ES cell studies. In those studies where conditional expression of Gata6 in a mouse ES cell line was generated, experimental expression of Gata6 was shown to be able to induce cardiac differentiation in a serum-free medium in a similar way as Gata4 and Gata5. However, some differences did appear among the cardiogenic GATA factors in those assays. Among those, Gata6 was less efficient at inducing cardiac differentiation (compared to its other sisters), and there were notable differences with regards to cardiac markers induced by each of them [12]. It has been suggested that the differences might reflect some early crosstalk among the genes themselves as they can activate expression of each other to different extents, with Gata6 specifically not able to activate the expression of Gata5. Among the possible explanations regarding the differences in genes activated by experimental Gata6 expression, it was suggested that some distinct cardiac cell types
were generated in this Gata6-programmed culture [94]. These observations highlight once more our need for the identification of specific target genes for those factors in order to improve our knowledge of the gene regulatory network (GRN) in which they are involved during cardiogenesis. To this end, we have recently undertaken work aiming to identify gata6 transcriptionally regulated genes (as well as those of its other sisters gata4 and gata5) on a genome-wide scale through RNA-seq analyses [24,25]. The data generated in that study provide a useful platform for future investigations that will further contribute to elucidating molecular pathways and the GRN underpinning embryonic cardiogenesis.

Other insights into GATA6 functions in cardiac differentiation came from recent work performed on long noncoding RNAs (lncRNAs) [95]. It was found that in humans, coding GATA6 resides adjacent to its antisense counterpart lncGATA6 (GATA6-AS1) on the genome, with both sharing the same promoter acting bidirectionally. Interestingly, it was found that GATA6-AS1 regulates the expression of its coding counterpart (GATA6) and thereby cardiomyocyte differentiation.

5. Direct and Indirect Roles of gata5 in Cardiac Development: Listen to the Fish!

In zebrafish, gata5-null embryos show a cardia bifida phenotype that resembles the mouse Gata4-null embryos. However, in mice, Gata5 homozygous embryos show no obvious phenotypes. Although this might indicate that functions may have been differentially assigned to these different GATA genes during evolution, it is worth noting that Gata5 mutant mouse embryos still express a truncated but potentially transcriptionally active isoform of Gata5 [96]. This is consistent with the observation of a shared characteristic among members of the GATA family to possess several alternative promoter-first exon combinations [97], whereas in chickens, two isoforms of GATA5 are produced [98]; one isoform excludes exon 2 (which was targeted in Gata5 mutant mice) and produces a truncated yet active protein, indicating that the observed phenotype in Gata5 mutant mice could potentially not reflect the absence of the full role of Gata5 in mouse cardiogenesis. Clear evidence, however, of an essential role of gata5 during cardiogenesis in zebrafish has emerged [43]. In fact, in contrast to Gata4-null mice, which seem to still express terminal differentiation markers, in zebrafish, mutant early markers (nkx2.5) and terminal differentiation markers are reduced [43]. That essential role of gata5 in heart formation as shown in zebrafish is further supported in studies in which it has demonstrated that smarcd3b cooperatively with gata5 promotes cardiovascular progenitor cell fate [99]. As mentioned above for Gata6, those data suggest the importance of interacting partners and consequently post-translational modifications in gata5 cardiac function. In line with this, it has been demonstrated that the SUMOylation of Gata5 is indispensable for its function in zebrafish cardiac development [100]. Yet, a conserved role of gata5 across species has emerged, as faust (gata5 mutants in zebrafish) did display endocardial defects [43], a phenotype also observed in mice [19]. These observations were further confirmed in recent studies in which a prominent role of mouse Gata5 in valve formation was described [15,44]. Valve development is a complex process that involves the expansion and differentiation of endocardial cells and their migration after epithelial-to-mesenchymal transformation (EMT) to form endocardial cushions at the atrioventricular canal (AVC) and within the outflow tract (OFT). A proper formation of the OFT requires not only functions of “cardiogenic” GATA factors but also a significant role from a member of the “haematopoietic” GATA group, namely GATA3. This is revealed in a study where Gata3 lethality was attenuated by catecholamine-based rescue [101]. The defects present in such mutants include a shorter OFT and reduced rotation of truncus arteriosus during the looping stages. Interestingly, individuals with DiGeorge syndrome with deletion in the 10p region that contains the GATA3 gene present with multiple problems, including cardiac defects [102,103]. However, Gata5, a member of the “cardiogenic” subfamily, is expressed in the myocardium, as well as the endocardium and derived endocardial cushions. Conditional inactivation of Gata5 in endocardial cells leads to hypoplastic hearts and a partially penetrant bicuspid aortic valve
(valve with two leaflets rather than the normal three) [44] suggesting an autonomous role of Gata5 in endocardial cushion formation, as discussed above, cardiac valve formation and compound mutants Gata5/Gata4 and Gata5/Gata6 have various defects in OFT in mice [15]. The above-mentioned data clearly support the importance of Gata5 in valve formation, and they also confirmed more recent studies in which the Gata5 loss-of-function mutation were found to be associated with congenital aortic valve [46] and Tetralogy of Fallot [45] (also see Table 1).

Recently it has also been demonstrated that GATA5 plays a significant role in endothelial homeostasis and blood pressure [20]. Keeping in mind the role of blood pressure in heart remodelling, those data implicate GATA5 as a major regulator of adult heart function. More recent investigations have provided the molecular mechanisms involved in Gata5’s remodelling function of the adult heart. They identified that the upstream regulation of Gata5 in that process is linked to activation by Sirt6, which results in the downregulation of the Gata5 repressor Nkx2.3 [104].

While those former observations are again indicative of genetic interactions among all three cardiogenic GATA factors in heart defects, attempts to clarify mechanisms by which gata5 functions during cardiogenesis have been made in studies using Xenopus as a model system [11,105]. Interestingly, the gata5 function has been shown to be downstream of its sisters gata4 and gata6 to allow differentiation of heart precursor cells to mature cardiomyocytes [11] (Figure 1A).

Further evidence for an essential and direct role of Gata5 in the process of heart formation has been provided in studies in which the conditional expression of Gata5 in the ES cell line was used. The cells have proven to be capable of promoting cardiogenesis in a serum-free culture condition [12]. In contrast to what was observed in Xenopus where gata5 function seems to favour subsequent differentiation of cardiac precursor cells [11] (Figure 1A), this mES cell context rather argues that Gata5 induction directs early mesoderm-committed progenitors to cardiac fate [12]. Here, it has been shown that Gata5 induction directs the development of cardiomyocytes as monitored by the phenotypical observation of beating sheets of cells that express cardiac differentiation markers and, more importantly, show a full range of action potential morphologies that are responsive to pharmacological stimulation [12]. Such a discovery provides scope for potential applications for drugs testing. These observations in mESCs that Gata5 is more potent when compared to its other sisters, Gata4 and Gata6, highlight once more our need for the identification of specific target genes for each of the cardiogenic GATA factors. In this regard, recent studies in Xenopus laevis were carried out by us to identify gata5-regulated genes on a genome-wide scale through RNA-seq analysis [24,25]. As mentioned for gata6 above, the data generated in that study provide a useful platform for future investigations that will further contribute to elucidating molecular pathways and the GRN that governs heart formation.

6. Direct and Indirect Roles of GATA4 in Cardiac Development: Is GATA4 the Boss?

GATA4 appears to be the most-studied of the three cardiogenic GATA factors, indicative of its role in cardiogenesis and possibly the complexity of its functions in that process. GATA4 is expressed throughout development and also in the adult heart. Clinical studies have linked its role in both human CHD, specifically atrial/ventricular septal defects [48,53,56,57,106,107] in heart defects in mice [47,48,78] (also see Table 1). Those defects were shown to result from Gata4 alone or from a combination with its other sisters [15,62]. However, some differences have been observed regarding the differences in the severity of the phenotypes depending on the species and methods used in the studies. In studies using P19, a cell line induced to form beating cardiomyocytes by the addition of DMSO, the depletion of GATA4 by the antisense strategy prevented terminal differentiation and promoted apoptosis, while GATA4 gain-of-function studies suggest ectopic beating cardiomyocytes [108] in the absence of DMSO [7,106]. Consistent with this, gain-of-function experiments in Xenopus embryos cause a premature expression of cardiac differentiation markers and induce heart marker expression in the presumptive
ectoderm and subsequently spontaneous cardiomyocyte beating [6, 8, 9, 11, 13]. However, most Gata4-null mice survive gastrulation and form differentiated myocardium, but show a ventral morphogenesis defect resulting in cardiia bifida [22, 23]. Those in vivo studies have shown that Gata4 is crucial for proper heart tube formation, ventral patterning and proper heart assembly [22, 23]. The observed cardiac defects in Gata4-null mice are supposed to be non-cell-autonomous, as Gata4−/− ES cells can contribute to an apparently normal heart in chimeric mice [23, 79]. Chimera studies also suggested that the ventral phenotype observed in Gata4−/−-null mice is due to lack of GATA4 in the endoderm [107] rather than in the mesoderm, indicative of Gata4 function involving downstream secreted factors emanating from the endoderm, which then induce cardiac differentiation in the adjacent mesoderm. That observation was confirmed in later studies in Xenopus where gata4 was shown to induce cardiac differentiation through Wnt signalling [9, 11] (also Figure 1A). In those studies, it was shown that β-catenin-dependent Wnt signalling restricts cardiogenesis via the inhibition of gata4 (and to some extent gata6 [32]) gene expression, where experimentally reinstating gata4 function overrides β-catenin-mediated inhibition and restores cardiogenesis [9, 32]. In turn, gata4 directly regulates wnt11b gene expression, which is required to a significant degree for mediating the cardiogenesis-promoting function of gata4 [9] (also see Figure 1A). In line with those data implicating the endoderm as a source of secreted factors for inducing cardiogenesis in the mesoderm, embryonic explant assays have implicated anterior endoderm as a tissue from which cardiac inductive cues are derived, including members of the Nodal, Bmp, Fgf and Wnt signalling pathways [109]. Explant assays in Xenopus identified dkk1 (a Wnt inhibitor) as a secreted factor required for the expression of hex1 in the endoderm associated with presumptive cardiac mesoderm [110, 111], again supporting the rationale behind endoderm-derived factors inducing cardiac fate in mesodermal cells. It is tempting to suggest an attractive model in which Gata4 plays a role in the inductive signals emanating from the endoderm to the adjacent mesoderm (Figure 2). Indeed, data from ES cells support such an assertion. Thus, as a direct overexpression of Gata4 in murine ES cells causes them to differentiate into the extraembryonic endoderm [112], a system to conditionally express Gata4 in cultured embryoid bodies (EBs) has been generated to evaluate the ability of Gata4 to direct cardiomyocyte fate [31]. In such a setting, the induction of Gata4 significantly increases the levels of Sox17 expression, a known endoderm specification gene [113], as well as Hex expression. In the above-mentioned studies where conditional Gata4 expressing cells were used, it appears that Gata4 acts upstream of Sox17 for the production of endoderm-derived heart-inducing factors [31]. Those data are consistent with previous observations in which the inhibition of Sox17 with RNA interference resulted in the suppression of cardiomyocyte differentiation, without altering endoderm formation [114]. More importantly, these authors have shown that Sox17 induces cardiomyogenesis in a non-cell-autonomous manner through the endodermal cardiogenic factor Hex [114] consistent with previous Xenopus studies [110, 115].

6.1. Co-Operative Activity with Gata4 in Cardiogenesis: With a Little Help from My Friends

While those mixed EB culture conditions have shown that the Gata4 function is to produce a cardiac-inducing endodermal signal, forced expression of Gata4 directly in embryonic mesoderm has proven not to be sufficient to induce cardiac fate [116]. Instead, Gata4 does promote cardiac specification and differentiation when coexpressed in noncardiac mesoderm with Tbx5 (Figure 3) and Baf60c [116]. The co-operative activity among Gata4 and other cardiac-specific transcription factor(s) for reprogramming various cell types into beating cardiomyocytes was confirmed in further studies but interestingly with different efficiencies [68, 75, 117–120]. Thus, it was reported that in vitro a minimum mixture of Gata4-Mef2c-Tbx5 (GTM) (Figure 3) directly induces cardiomyocyte-like cells (iCMs) from mouse fibroblasts [121]. Subsequently, other groups also reported the generation of functional cardiomyocytes from mouse fibroblasts with various combinations of transcription factors that include either GMT plus Hand2 (GHMT) (Figure 3) or Mef2c, Myocardin (Myoc) and Tbx5 or using microRNAs [122–124]. Although in those in vitro settings full reprogram-
of Sox17 with RNA interference resulted in the suppression of cardiomyocyte differentiation. Because those iCMs require a coculture with murine cardiomyocytes to differentiate into beating cardiomyocytes, it was suggested that they might be similar to the early stage of embryonic cardiomyocytes before the start of contraction or alternatively that they might be some partially reprogrammed cardiomyocytes at a preinduced pluripotent (pre-iPSC) stage that can become fully pluripotent with additional stimuli (ibid). In this regard, it is worth noting that the stoichiometry of the transcription factors is believed to play a crucial role in those settings for determining the cell fate of the transduced cells into iCMs [120] or into smooth muscle-like cells. As the addition of MYOC upregulates sarcomeric genes and MESP1 induces intracellular Ca^{2+} oscillations [126], it was suggested that MYOC and MESP1 differentially regulate cardiac gene expression in human cardiac reprogramming (ibid). Although several other factors (for instance the gene family of Friends of GATA—also known as FOG) have been described to interact with GATA4, it is expected that the identification of the others will surely follow as further progress is made towards deciphering the GRN involved in driving cardiogenesis. A body of work confirms the importance of the FOG in regulating GATA factors functioning during cardiac differentiation and also provides the molecular mechanisms involved in their interactions with GATA4 [127–130] (also see Figure 3). Other studies identified ART27 as a GATA4 corepressor interacting with the Friends of GATA2 (FOG2) and NKX2.5, involved in downregulating cardiac-specific genes [131]. Whatever mechanisms are involved in the regulation of GATA4 function during cardiac differentiation, these data clearly highlighted the crucial role played by GATA4 in cardiomyocyte development.

**Figure 2.** Factors emanating from endoderm induce mesodermal layer formation. GATA4 in endoderm controls a non-cell-autonomous pathway for cardiac myogenesis. Other transcription factors and signalling molecules induce GATA4 in endoderm, which in turn induces secreted molecules that promote cardiac differentiation of the underlying cardiac progenitors to cardiomyocytes. This model did not exclude a direct function of GATA4 in the mesoderm itself to promote cardiac differentiation as depicted by the question mark (?). Abbreviations: Eomes, Eomesodermin; Bra, Brachyury; Mesp, Mesoderm Posterior; Nkx, Nkx gene; Tbx, Tbx gene; Gata4, Gata4 gene.
6.2. Gata4 Possesses Intrinsic Cardiogenic Activities

Although the above-mentioned evidence established a co-operative activity of GATA4 with other factors in cardiogenesis, GATA4’s ability to programme (on its own) cardiac fate cannot be ruled out. Indeed, through the conditional expression of Gata4 in a mouse embryonic stem cell line, Gata4 was shown to be sufficient to highly expand cardiac cells [12], as monitored at the phenotypical level as well as transcriptomics followed by gene ontology showing a high enrichment of a cardiac muscle gene set [12]. Further efforts have been made to shed light on the cardiogenic activity of GATA4 by dissecting the role played by different domains that make up the GATA4 protein. It turns out that its cardiogenic activity requires a sequence stretch of 24 amino acids (129 to 152) that is also needed for GATA4’s interaction with the chromatin remodelling protein BAF60c [132]. As the same domain was shown not to be essential for its endodermal induction activity, this suggests that it acts as a cell-type-specific transcriptional activation domain. The serine at position 105, which is known to be phosphorylated by MAP kinase [133] and required for myocyte survival and hypertrophy [133], has been shown to be dispensable for the GATA4 induction of cardiogenesis. That same serine residue has been shown to be required for GATA4 to synergise with SRF but interestingly not with other important cardiogenic transcription factors, such as TBX5 and NKF2.5 [132]. Furthermore, it was demonstrated that the carboxy terminal region, composed of amino acid 362–400, physically and functionally interacts with CDK4, resulting in the enhancement of the cardiogenic activity of GATA4 [134]. Those data confirm the relationship between GATA4 and cyclin molecules as described in previous studies in which cyclin molecules were shown to be Gata4 targets [135,136].

The above-mentioned data clearly indicate the importance of phosphorylation in the regulation of GATA4 cardiac function (Figure 3). They confirm previous studies that demonstrated GATA4 is phosphorylated by PKC at serine 419/420, allowing it to interact with STAT1 and transactivate the Nppa promoter [136]. Those post-translational modifica-
tions were reported to be crucial for the cardiac hypertrophic function of Gata4. Thus, over the past several years, the molecular mechanisms behind cardiac hypertrophy have been investigated [34,137–140]. More evidence for the implication of GATA4 phosphorylation in cardiac diseases was provided in another study [67]. Here, the authors demonstrated that the repression of GATA4 caused by its phosphorylation by beta-catenin leads to some observed diseases in humans and mice (ibid). These data are promising for the development of potential treatment for heart failure therapy and for heart repair after injury.

6.3. Context-Dependent Activities of GATA4

As just mentioned above with GATA4 phosphorylation at various sites (Figure 3), post-translational modifications account for many GATA4 activities in heart formation. The same thing was confirmed in other studies [141]. Another level of complexity in the mechanisms by which Gata4 exerts its activities has been provided by studies in which a context-dependent regulation of Gata4 was shown to take place via tuning its functions to avoid its dysfunction that would otherwise result in some heart diseases, such as arrhythmias [142]. While the initial heart tube is formed and elongated, specific regions differentiate and start to proliferate to form expanding atria and ventricle chambers that are divided by the atrioventricular canal. An important study was able to demonstrate that Gata4 plays a crucial role in allowing those chambers to keep their identities for proper heart development [64]. The authors assessed the genome-wide distribution of H3K27ac by ChiP-seq. Although the genome contains thousands of occupied GATA sites, the question of why only a fraction of these sites have AV canal-specific properties was evident. The investigation found that GATA-binding elements in AV canal-specific enhancers recruit a Gata4/Smad4/Histone acetylase transcriptional activation complex in the AV canal and a Gata4/Hey1,2/Histone deacetylase transcriptional repression complex in the chambers [64]. The transcriptional activation complex induces H3K27 acetylation that is associated with AV canal gene activation, and the repression complex induces H3K27 deacetylation associated with the repression of AV canal genes in the chamber [64,66]. Those data that demonstrate the importance of epigenetic modifications in regulating Gata4 functions (Figure 3) (and those of other factors) in cardiogenesis confirm other findings. In fact, work by Si et al. suggests that the Smad4-mediated Bmp2 signalling pathway affects the histone H3 acetylation of Gata4 and Nkx2.5 genomic loci, which is essential for their regulation [65]. Those data are in line with other reports on system biology involving other cardiac factors [143]. The above-mentioned data not only demonstrate the importance of epigenetic modifications of the Gata4 locus during cardiac development, but they also suggest the crucial role played by those post-translational modifications in heart development (Figure 3). Indeed, other investigations demonstrate that GATA4 binds and participates in establishing an active chromatin region by stimulating the H3K27ac deposit, which facilitates Gata4-driven gene expression [144].

Altogether, the data presented above clearly demonstrate the crucial role of Gata4 (among the cardiogenic GATA factors) during heart formation. As described for gata5 and 6 above, we also performed genome-wide analyses for the identification of specific targets for gata4 during cardiomyogenesis [24,25]. Our work shows that sox7 and sox18, whose function in cardiomyogenesis has previously been described [145], are specifically regulated by gata4 in both Xenopus and mammalian systems (ES cells) [24,25] (Figure 1B). These studies also identified a wealth of target genes specifically regulated by gata4 that pave the way for further investigations into elucidating GRNs that are involved downstream of gata4 [25] during cardiomyogenesis. Figure 4 is a proposed model to depict GATA4, 5 and 6 functions during heart formation.
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW 14 of 21

The crucial role played by those post-translational modifications in heart development is similar to those seen with Holt–Oram syndrome mutations in \( \text{GATA4} \) and its other sisters \( \text{GATA5} \) and \( \text{GATA6} \). Interacting with other partners allows GATA factors to regulate cardiogenesis through signalling pathways, some of which have been discovered in recent years, with the observation that the cardiac malformation seen in humans, when \( \text{GATA4} \) is disrupted, is similar to those seen with Holt–Oram syndrome mutations in \( \text{TBX5} \) and when \( \text{NKX2.5} \) is mutated. Although many other studies have also uncovered other interacting partners of \( \text{GATA4} \) beyond those mentioned in this review, it is worth speculating that many others will be discovered in the future not only for \( \text{GATA4} \) but also for its other sisters \( \text{GATA5} \) and \( \text{GATA6} \). Interacting with other partners allows GATA factors to regulate cardiogenesis through signalling pathways, some of which have been discovered in recent years, with likely more to come. The recent identification of targets specifically regulated by each of these factors during cardiogenesis opens the way to studies that will allow elucidating not only for which part of the heart those factors are required but also the molecular mechanisms involved.

**Funding:** This work is supported by the British Heart Foundation (BHF): programme grant number: RG/18/8/33673 to Professor Stefan Hoppler.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** I would like to thank Stefan Hoppler for providing critical comments as well as valuable and constructive suggestions for the manuscript.

**Conflicts of Interest:** The author declares no competing or financial interest.
References

1. McFadden, D.G.; Olson, E.N. Heart development: Learning from mistakes. Curr. Opin. Genet. Dev. 2002, 12, 328–335. [CrossRef]  
2. Fahed, A.C.; Gelb, B.D.; Seidman, J.G.; Seidman, C.E. Genetics of congenital heart disease: The glass half empty. Circ. Res. 2013, 112, 707–720. [CrossRef] [PubMed]  
3. Patient, R.K.; McGee, J.D. The GATA family (vertebrates and invertebrates). Curr. Opin. Genet. Dev. 2002, 12, 416–422. [CrossRef]  
4. Zon, L.I.; Mather, C.; Burgess, S.; Bolce, M.E.; Harland, R.M.; Orkin, S.H. Expression of GATA-binding proteins during embryonic development in Xenopus laevis. Proc. Natl. Acad. Sci. USA 1991, 88, 10642–10646. [CrossRef]  
5. Molkenkamp, J.D. The zinc finger-containing transcription factors GATA4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J. Biol. Chem. 2000, 275, 38949–38952. [CrossRef]  
6. Jiang, Y.; Evans, T. The Xenopus GATA-4/5/6 genes are associated with cardiac specification and can regulate cardiac-specific transcription during embryogenesis. Dev. Biol. 1996, 174, 258–270. [CrossRef]  
7. Grepin, C.; Nemer, G.; Nemer, M. Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development 1997, 124, 2387–2395. [CrossRef]  
8. Latinkic, B.V.; Kotecha, S.; Mohun, T.J. Induction of cardiomyocytes by GATA4 in Xenopus ectodermal explants. Development 2003, 130, 3865–3876. [CrossRef]  
9. Afouda, B.A.; Martin, J.; Liu, F.; Ciau-Uitz, A.; Patient, R.; Hoppler, S. GATA transcription factors integrate Wnt signalling during heart development. Development 2008, 135, 3185–3190. [CrossRef]  
10. Afouda, B.A.; Hoppler, S. Xenopus explants as an experimental model system for studying heart development. Trends. Cardiovasc. Med. 2009, 19, 220–226. [CrossRef]  
11. Afouda, B.A.; Hoppler, S. Different requirements for GATA factors in cardiogenesis are mediated by non-canonical Wnt signalling. Dev. Dyn. 2011, 240, 649–662. [CrossRef] [PubMed]  
12. Turbendian, H.K.; Gordillo, M.; Tsai, S.Y.; Lu, J.; Kang, G.; Liu, T.C.; Tang, A.; Liu, S.; Fishman, G.I.; Evans, T. GATA factors efficiently direct cardiac fate from embryonic stem cells. Development 2013, 140, 1639–1644. [CrossRef] [PubMed]  
13. Liang, Q.; De Windt, L.J.; Witt, S.A.; Kimball, T.R.; Markham, B.E.; Molkenkamp, J.D. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J. Biol. Chem. 2001, 276, 30245–30253. [CrossRef] [PubMed]  
14. Jiang, Y.; Tarzami, S.; Burch, J.B.; Evans, T. Common role for each of the cGATA-4/5/6 genes in the regulation of cardiac morphogenesis. Dev. Genet. 1998, 22, 263–277. [CrossRef]  
15. Laforest, B.; Nemer, M. GATA5 interacts with GATA4 and GATA6 in outflow tract development. Dev. Biol. 2011, 358, 368–378. [CrossRef]  
16. Gharibeh, L.; Komati, H.; Bosse, Y.; Boodhwani, M.; Heydarpour, M.; Fortier, M.; Hassanzadeh, R.; Ngu, J.; Mathieu, P.; Body, S.; et al. GATA6 Regulates Aortic Valve Remodeling, and Its Haploinsufficiency Leads to Right-Left Type Bicuspid Aortic Valve. Circulation 2018, 138, 1025–1035. [CrossRef]  
17. Xu, Y.J.; Di, R.M.; Qiao, Q.; Li, X.M.; Huang, R.T.; Xue, S.; Liu, X.Y.; Wang, J.; Yang, Y.Q. GATA6 loss-of-function mutation contributes to congenital bicuspid aortic valve. Gene 2018, 663, 115–120. [CrossRef]  
18. Gharibeh, L.; Yamak, A.; Whitcomb, J.; Lu, A.; Joyal, M.; Komati, H.; Liang, W.; Fiset, C.; Nemer, M. GATA6 is a regulator of sinus node development and heart rhythm. Proc. Natl. Acad. Sci. USA 2021, 118. [CrossRef]  
19. Nemer, G.; Nemer, M. Cooperative interaction between GATA5 and NF-ATc regulates endothelial-endocardial differentiation of cardiogenic cells. Development 2002, 129, 4045–4055. [CrossRef]  
20. Messaoudi, S.; He, Y.; Gutsol, A.; Wight, A.; Hebert, R.L.; Vilmundarson, R.O.; Makrigiannis, A.P.; Chalmers, J.; Hamet, P.; Tremblay, J.; et al. Endothelial Gata5 transcription factor regulates blood pressure. Nat. Commun. 2015, 6, 8835. [CrossRef]  
21. Kelley, C.; Blumberg, H.; Zon, L.I.; Evans, T. GATA4 is a novel transcription factor expressed in endocardium of the developing heart. Development 1993, 118, 817–827. [CrossRef] [PubMed]  
22. Molkentink, J.D.; Lin, Q.; Duncan, S.A.; Olson, E.N. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 1997, 11, 1061–1072. [CrossRef] [PubMed]  
23. Kuo, C.T.; Morrissey, E.E.; Anandappa, R.; Sigrist, K.; Lu, M.M.; Parmacek, M.S.; Soudais, C.; Leiden, J.M. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 1997, 11, 1048–1060. [CrossRef] [PubMed]  
24. Afouda, B.A.; Lynch, A.T.; de Paiva Alves, E.; Hoppler, S. Genome-wide transcriptomics analysis identifies sox7 and sox18 as specifically regulated by gata4 in cardiomyogenesis. Dev. Biol. 2018, 434, 108–120. [CrossRef]  
25. Afouda, B.A.; Lynch, A.T.; de Paiva Alves, E.; Hoppler, S. Genome-wide transcriptomics analysis of genes regulated by GATA4, 5 and 6 during cardiomyogenesis in Xenopus laevis. Data Brief. 2018, 17, 559–563. [CrossRef]  
26. Peterkin, T.; Gibson, A.; Patient, R. Redundancy and evolution of GATA factor requirements in development of the myocardium. Dev. Biol. 2007, 311, 623–635. [CrossRef]  
27. Sam, J.; Mercer, E.J.; Torregroza, I.; Banks, K.M.; Evans, T. Specificity, redundancy and dosage thresholds among gata4/5/6 genes during zebrafish cardiogenesis. Biol. Open 2020, 9. [CrossRef]  
28. Liu, J.; Cheng, H.; Xiang, M.; Zhou, L.; Wu, B.; Moskowitz, I.P.; Zhang, K.; Xie, L. Gata4 regulates hedgehog signaling and Gata6 expression for outflow tract development. PLoS Genet. 2019, 15, e1007711. [CrossRef]  
29. Nemer, G.; Nemer, M. Transcriptional activation of BMP-4 and regulation of mammalian organogenesis by GATA-4 and -6. Dev. Biol. 2003, 254, 131–148. [CrossRef]
30. Peterkin, T.; Gibson, A.; Patient, R. GATA-6 maintains BMP-4 and Nkx2 expression during cardiomyocyte precursor maturation. *EMBO J.* 2003, 22, 4260–4273. [CrossRef]

31. Holtzinger, A.; Rosenfield, G.E.; Evans, T. Gata4 directs development of cardiac-inducing endoderm from ES cells. *Dev. Biol.* 2010, 337, 63–73. [CrossRef] [PubMed]

32. Martin, J.; Afouda, B.A.; Hoppler, S. Wnt/beta-catenin signalling regulates cardiomyogenesis via GATA transcription factors. *J. Anat.* 2010, 216, 92–107. [CrossRef] [PubMed]

33. Novikov, N.; Evans, T. Tmem88a mediates GATA-dependent specification of cardiomyocyte progenitors by restricting WNT signaling. *Development* 2013, 140, 3787–3798. [CrossRef] [PubMed]

34. Yu, W.; Huang, X.; Tian, X.; Zhang, H.; He, L.; Wang, Y.; Nie, Y.; Hu, S.; Lin, Z.; Zhou, B.; et al. GATA4 regulates Fgf16 to promote heart repair after injury. *Development* 2016, 143, 936–949. [CrossRef] [PubMed]

35. Morrisey, E.E.; Tang, Z.; Sigrist, K.; Lu, M.M.; Jiang, F.; Ip, H.S.; Farmacek, M.S. GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. *Genes Dev.* 1998, 12, 3579–3590. [CrossRef]

36. Koutsourakis, M.; Langeveld, B.; Patient, R.; Beddington, R.; Grosse, F. The transcription factor GATA6 is essential for early extraembryonic development. *Development* 1999, 126, 723–732. [CrossRef]

37. Gove, C.; Walsmley, M.; Nijjar, S.; Bertwistle, D.; Guille, M.; Partington, G.; Bomford, A.; Patient, R. Over-expression of GATA-6 in Xenopus embryos blocks differentiation of heart precursors. *EMBO J.* 1997, 16, 355–368. [CrossRef]

38. Narita, N.; Heikinheimo, M.; Bielinska, M.; White, R.A.; Wilson, D.B. The gene for transcription factor GATA-6 resides on mouse chromosome 18 and is expressed in myocardium and vascular smooth muscle. *Genomics* 1996, 36, 345–348. [CrossRef]

39. Charron, F.; Paradis, P.; Bronchain, O.; Nemer, M. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. *Mol. Cell. Biol.* 1999, 19, 4355–4365. [CrossRef]

40. Kodo, K.; Nishizawa, T.; Furutani, M.; Arai, S.; Yamamura, E.; Joo, K.; Takahashi, T.; Matsuoka, R.; Yamagishi, H. GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. *Proc. Natl. Acad. Sci. USA* 2009, 106, 13933–13938. [CrossRef]

41. van Berlo, J.H.; Elrod, J.W.; van den Hoogenhof, M.M.; York, A.J.; Aronow, B.J.; Duncan, S.A.; Molkentin, J.D. The transcription factor GATA6 regulates pathological cardiac hypertrophy. *Circ. Res.* 2010, 107, 1032–1040. [CrossRef] [PubMed]

42. Tian, Y.; Yuan, L.; Goss, A.M.; Wang, T.; Yang, J.; Lepore, J.J.; Zhou, D.; Schwartz, R.J.; Patel, V.; Cohen, E.D.; et al. Characterization and in vivo pharmacological rescue of a Wnt2-Gata6 pathway required for cardiac inflow tract development. *Dev. Cell* 2010, 18, 275–287. [CrossRef]

43. Reiter, J.F.; Alexander, J.; Rodaway, A.; Yelon, D.; Patient, R.; Holder, N.; Stainier, D.Y. Gata5 is required for the development of the heart and endoderm in zebrafish. *Genes Dev.* 1999, 13, 2983–2995. [CrossRef] [PubMed]

44. Laforest, B.; Andelfinger, G.; Nemer, M. Loss of Gata5 in mice leads to bicuspid aortic valve. *J. Clin. Investig.* 2011, 121, 2876–2887. [CrossRef]

45. Wei, D.; Bao, H.; Liu, X.Y.; Zhou, N.; Wang, Q.; Li, R.G.; Xu, Y.J.; Yang, Y.Q. GATA4 loss-of-function mutations underlie tetralogy of fallot. *Int. J. Med. Sci.* 2013, 10, 34–42. [CrossRef]

46. Shi, L.M.; Tao, J.W.; Qiu, X.B.; Wang, J.; Yuan, F.; Xu, L.; Liu, H.; Li, R.G.; Xu, Y.J.; Wang, Q.; et al. GATA5 loss-of-function mutations associated with congenital cuspид aortic valve. *Int. J. Mol. Med.* 2014, 33, 1219–1226. [CrossRef]

47. Singh, M.K.; Li, Y.; Li, S.; Cobb, R.M.; Zhou, D.; Lu, M.M.; Epstein, J.A.; Morrisey, E.E.; Gruber, P.J. Gata4 and Gata5 cooperatively regulate cardiac myocyte proliferation in mice. *J. Biol. Chem.* 2010, 285, 1765–1772. [CrossRef]

48. Garg, V.; Kathiriya, I.S.; Barnes, R.; Schluterman, M.K.; King, I.N.; Butler, C.A.; Rothrock, C.R.; Eapen, R.S.; Hirayama-Yamada, K.; Joo, K.; et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. *Nature* 2003, 424, 443–447. [CrossRef]

49. Rajagopal, S.K.; Ma, Q.; Obler, D.; Shen, J.; Manichaikul, A.; Tomita-Mitchell, A.; Boardman, K.; Briggs, C.; Garg, V.; Srivastava, D.; et al. Spectrum of heart disease associated with murine and human GATA4 mutation. *J. Mol. Cell Cardiol.* 2007, 43, 677–685. [CrossRef]

50. Moskowitz, I.P.; Wang, J.; Peterson, M.A.; Pu, W.T.; Mackinnon, A.C.; Oubourgh, L.; Chu, G.C.; Sarkar, M.; Berul, C.; Smoot, L.; et al. Transcription factor genes Sma4d and Gata4 cooperatively regulate cardiac valve development. [corrected]. *Proc. Natl. Acad. Sci. USA* 2011, 108, 4006–4011. [CrossRef]

51. Ounzain, S.; Kobayashi, S.; Peterson, R.E.; He, A.; Motterle, A.; Samani, N.J.; Menick, D.R.; Pu, W.T.; Liang, Q.; Chong, N.W. Cardiac expression of ms1/STARS, a novel gene involved in cardiac development and disease, is regulated by GATA4. *Mol. Cell Biol.* 2012, 32, 1830–1843. [CrossRef] [PubMed]

52. Misra, C.; Sachan, N.; McNally, C.R.; Koenig, S.N.; Nichols, H.A.; Guggilam, A.; Lucchesi, P.A.; Pu, W.T.; Srivastava, D.; Garg, V. Congenital heart disease-causing Gata4 mutation displays functional deficits in vivo. *PLoS Genet.* 2012, 8, e1002690. [CrossRef] [PubMed]

53. Wang, E.; Sun, S.; Qiao, B.; Duan, W.; Huang, G.; An, Y.; Xu, S.; Zheng, Y.; Su, Z.; Gu, X.; et al. Identification of functional mutations in GATA4 in patients with congenital heart disease. *PLoS ONE* 2013, 8, e62138. [CrossRef] [PubMed]

54. Misra, C.; Chang, S.W.; Basu, M.; Huang, N.; Garg, V. Disruption of myocardial Gata4 and Tbx5 results in defects in cardiomyocyte proliferation and atrioventricular septation. *Hum. Mol. Genet.* 2014, 23, 5025–5035. [CrossRef]

55. Han, H.; Chen, Y.; Liu, G.; Han, Z.; Zhao, Z.; Tang, Y. GATA4 transgenic mice as an in vivo model of congenital heart disease. *Int. J. Mol. Med.* 2015, 35, 1545–1553. [CrossRef]
56. Li, R.G.; Xu, Y.J.; Wang, J.; Liu, X.Y.; Yuan, F.; Huang, R.T.; Xue, S.; Li, L.; Liu, H.; Li, Y.J.; et al. GATA4 Loss-of-Function Mutation and the Congenital Bicuspid Aortic Valve. *Am. J. Cardiol.* 2018, 121, 469–474. [CrossRef]
57. Dixit, R.; Narasimhan, C.; Balekundi, V.; Agrawal, D.; Kumar, A.; Mohapatra, B. Functionally significant, novel GATA4 variants are frequently associated with Tetralogy of Fallot. *Hum. Mutat.* 2018, 39, 1957–1972. [CrossRef]
58. LaHaye, S.; Majumdar, U.; Yashahara, J.; Koenig, S.N.; Matos-Nieves, A.; Kumar, R.; Garg, V. Developmental origins for semilunar valve stenosis identified in mice harboring congenital heart disease-associated GATA4 mutation. *Dis. Model. Mech.* 2019, 12. [CrossRef]
59. Li, B.; Li, Z.; Yang, J.; Hong, N.; Jin, L.; Xu, Y.; Fu, Q.; Sun, K.; Yu, Y.; Lu, Y.; et al. Predisposition to atrioventricular septal defects may be caused by SOX7 variants that impair interaction with GATA4. *Mol. Genet. Genom.* 2022. [CrossRef]
60. Holtzinger, A.; Evans, T. GATA4 regulates the formation of multiple organs. *Development* 2005, 132, 4005–4014. [CrossRef]
61. Watt, A.J.; Battle, M.A.; Li, J.; Duncan, S.A. GATA4 is essential for formation of the proepicardium and regulates cardiogenesis. *Proc. Natl. Acad. Sci. USA* 2004, 101, 12573–12578. [CrossRef] [PubMed]
62. Zhao, R.; Watt, A.J.; Battle, M.A.; Li, J.; Bondow, B.J.; Duncan, S.A. Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. *Dev. Biol.* 2008, 317, 614–619. [CrossRef] [PubMed]
63. Rivera-Feliciano, J.; Lee, K.H.; Kong, S.W.; Rajagopal, S.; Ma, Q.; Springer, Z.; Izumo, S.; Tabin, C.J.; Pu, W.T. Development of heart valves requires GATA4 expression in endothelial-derived cells. *Development* 2006, 133, 3607–3618. [CrossRef] [PubMed]
64. Stefanovic, S.; Barnett, P.; van Duijvenboden, K.; Weber, D.; Gessler, M.; Christoffels, V.M. GATA-dependent regulatory switches establish atrioventricular canal specificity during heart development. *Nat. Commun.* 2014, 5, 5680. [CrossRef]
65. Si, L.; Shi, J.; Gao, W.; Zheng, M.; Liu, L.; Zhu, J.; Tian, J. Smad4 mediated BMP2 signal is essential for the regulation of GATA4 and Nkx2.5 by the histone H3 acetylation in H9c2 cells. *Biochem. Biophys. Res. Commun.* 2014, 450, 81–86. [CrossRef]
66. Stefanovic, S.; Christoffels, V.M. GATA4-dependent transcriptional and epigenetic control of cardiac lineage specification and differentiation. *Cell Mol. Life Sci.* 2015, 72, 3871–3881. [CrossRef]
67. Iyer, L.M.; Nagarajan, S.; Woeller, M.; Schoger, E.; Khadjeh, S.; Zafriou, M.P.; Kari, V.; Herting, J.; Fang, S.T.; Weber, T.; et al. A context-specific cardiac beta-catenin and GATA4 interaction influences TCF7L2 occupancy and remodels chromatin driving disease progression in the adult heart. *Nucleic Acids Res.* 2018, 46, 2850–2867. [CrossRef]
68. Stone, N.R.; Gifford, C.A.; Thomas, R.; Pratt, K.J.B.; Samse-Knapp, K.; Mohamed, T.M.A.; Radzinsky, E.M.; Schricker, A.; Ye, L.; Yu, P.; et al. Context-Specific Transcription Factor Functions Regulate Epigenomic and Transcriptional Dynamics during Cardiac Reprogramming. *Cell Stem Cell* 2019, 25, 87–102.e109. [CrossRef]
69. Nemer, M. Genetic insights into normal and abnormal heart development. *Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol.* 2008, 17, 48–54. [CrossRef]
70. Meganathan, K.; Sotiriadou, I.; Natarajan, K.; Hescheler, J.; Sachinidis, A. Signaling molecules, transcription growth factors and other regulators revealed from in-vivo and in-vitro models for the regulation of cardiac development. *Int. J. Cardiol.* 2015, 183, 117–128. [CrossRef]
71. Whitcomb, J.; Gharibeh, L.; Nemer, M. From embryogenesis to adulthood: Critical role for GATA factors in heart development and function. *IUBMB Life* 2020, 72, 53–67. [CrossRef] [PubMed]
72. Crispino, J.D.; Lodish, M.B.; Thurberg, B.L.; Litovsky, S.H.; Collins, T.; Molkentin, J.D.; Orkin, S.H. Proper coronary vascular differentiation and heart morphogenesis depend on interaction of GATA4 with FOG cofactors. *Genes Dev.* 2001, 15, 839–844. [CrossRef] [PubMed]
73. Padang, R.; Bagnall, R.D.; Richmond, D.R.; Bannon, P.G.; Semsarian, C. Rare non-synonymous variations in the transcriptional activation domains of GATA5 in bicuspid aortic valve disease. *J. Mol. Cell. Cardiol.* 2012, 53, 277–281. [CrossRef] [PubMed]
74. Yang, Y.Q.; Wang, X.H.; Tan, H.W.; Jiang, W.F.; Fang, W.Y.; Liu, X. Prevalence and spectrum of GATA6 mutations associated with familial atrial fibrillation. *Int. J. Cardioiol.* 2015, 155, 494–496. [CrossRef] [PubMed]
75. Chen, J.X.; Krane, M.; Deutsch, M.A.; Wang, L.; Rav-Acha, M.; Greigore, S.; Engels, M.C.; Rajarajan, K.; Karra, R.; Abel, E.D.; et al. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. *Circ. Res.* 2018, 122, 50–55. [CrossRef] [PubMed]
76. Jiang, J.Q.; Li, R.G.; Wang, J.; Liu, X.Y.; Xu, Y.J.; Fang, W.Y.; Chen, X.Z.; Zhang, W.; Wang, X.Z.; Yang, Y.Q. Prevalence and spectrum of GATA5 mutations associated with congenital heart disease. *Int. J. Cardiol.* 2013, 165, 570–573. [CrossRef] [PubMed]
77. Zhang, X.L.; Dai, N.; Tang, K.; Chen, Y.Q.; Chen, W.; Wang, J.; Zhao, C.M.; Yuan, F.; Qiu, X.B.; Qu, X.K.; et al. GATA5 loss-of-function mutation in familial dilated cardiomyopathy. *Int. J. Mol. Med.* 2015, 35, 763–770. [CrossRef]
78. Prendiville, T.W.; Guo, H.; Lin, Z.; Zhou, P.; Stevens, S.M.; He, A.; VanDusen, N.; Chen, J.; Zhong, L.; Wang, D.Z.; et al. Novel Roles of GATA4/6 in the Postnatal Heart Identified through Temporally Controlled, Cardiomyocyte-Specific Gene Inactivation by Adeno-Associated Virus Delivery of Cre Recombinase. *PLoS ONE* 2015, 10, e0128105. [CrossRef]
79. Narita, N.; Bielinska, M.; Wilson, D.B. Cardiomyocyte differentiation by GATA4-deficient embryonic stem cells. *Development* 1997, 124, 3755–3764. [CrossRef]
80. Xin, M.; Davis, C.A.; Molkentin, J.D.; Lien, C.L.; Duncan, S.A.; Richardson, J.A.; Olson, E.N. A threshold of GATA4 and GATA6 expression is required for cardiovascular development. *Proc. Natl. Acad. Sci. USA* 2006, 103, 11189–11194. [CrossRef]
81. Maitra, M.; Schluterman, M.K.; Nichols, H.A.; Richardson, J.A.; Lo, C.W.; Srivastava, D.; Garg, V. Interaction of Gata4 and Gata6 with Tbx5 is critical for normal cardiac development. *Dev. Biol.* 2009, 326, 368–377. [CrossRef]
82. Borok, M.J.; Papazioanou, V.E.; Sussel, L. Unique functions of Gata4 in mouse liver induction and heart development. Dev. Biol. 2016, 410, 213–222. [CrossRef] [PubMed]
83. Merika, M.; Orkin, S.H. DNA-binding specificity of GATA family transcription factors. Mol. Cell Biol. 1993, 13, 3999–4010. [CrossRef] [PubMed]
84. Ko, L.J.; Engel, J.D. DNA-binding specificities of the GATA transcription factor family. Mol. Cell Biol. 1993, 13, 4011–4022. [CrossRef] [PubMed]
85. Haworth, K.E.; Kotecha, S.; Mohun, T.J.; Latinkic, B.V. GATA4 and GATA5 are essential for heart and liver development in mice. Dev. Biol. 2000, 226, 213–224. [CrossRef] [PubMed]
86. Maitra, M.; Koenig, S.N.; Srivastava, D.; Garg, V. Identification of GATA6 sequence variants in patients with congenital heart defects. Pediatr. Res. 2010, 68, 281–285. [CrossRef]
87. Nam, Y.S.; Kim, Y.; Joung, H.; Kwon, D.H.; Choe, N.; Min, H.K.; Kim, Y.S.; Kim, H.S.; Kim, D.K.; Cho, Y.K.; et al. Small heterodimer partner blocks cardiac hypertrophy by interfering with GATA6 signaling. Circ. Res. 2014, 115, 493–503. [CrossRef]
88. Sharma, A.; Wasson, L.K.; Willeco, J.A.; Morton, S.U.; Gorham, J.M.; DeLaughter, D.M.; Neyazi, M.; Schmid, M.; Agarwal, R.; Jang, M.Y.; et al. GATA6 mutations in hiPSCs inform mechanisms for maldevelopment of the heart, pancreas, and diaphragm. Elife 2020, 9. [CrossRef]
89. van Berlo, J.H.; Aronow, B.J.; Molkentin, J.D. Parsing the roles of the transcription factors GATA-4 and GATA-6 in the adult cardiac hypertrophic response. PLoS ONE 2013, 8, e84591. [CrossRef]
90. Wada, H.; Hasegawa, K.; Morimoto, T.; Kakita, T.; Yanazume, T.; Sasayama, S. A p300 protein as a coactivator of GATA-6 in the transcription of the smooth muscle-myosin heavy chain gene. J. Biol. Chem. 2000, 275, 25330–25335. [CrossRef] [PubMed]
91. Brewer, A.; Gove, C.; Davies, A.; McNulty, C.; Barrow, D.; Koutsourakis, M.; Farzaneh, F.; Pizzey, J.; Bompford, A.; Patient, R. The human and mouse GATA-6 genes utilize two promoters and two initiation codons. J. Biol. Chem. 1999, 274, 38004–38016. [CrossRef] [PubMed]
92. MacNeill, C.; Ayres, B.; Laverriere, A.C.; Burch, J.B. Transcripts for functionally distinct isoforms of chicken GATA-5 are differentially expressed from alternative first exons. J. Biol. Chem. 1997, 272, 8396–8401. [CrossRef] [PubMed]
93. Lou, X.; Deshwar, A.R.; Crump, J.G.; Scott, I.C. Smarcd3b and Gata5 promote a cardiac progenitor fate in the zebrafish embryo. Development 2011, 138, 3113–3123. [CrossRef]
94. Chen, H.; Sun, W.; Zhu, J.; Yuan, H.; Chu, M.; Wen, B. Modification of cardiac transcription factor Gata6 by SUMO. Biochimie 2020, 170, 212–218. [CrossRef] [PubMed]
95. Jha, R.; Li, D.; Wu, Q.; Ferguson, K.E.; Forghani, P.; Gibson, G.C.; Xu, C. A long non-coding RNA GATA6-AS1 adjacent to GATA6 is required for vascular smooth muscle cell differentiation after mTORC1 inhibition. Sci. Signal. 2015, 8, ra44. [CrossRef] [PubMed]
96. Guo, J.; Wang, Z.; Wu, J.; Liu, M.; Li, M.; Sun, Y.; Huang, W.; Li, Y.; Zhang, Y.; Tang, W.; et al. Endothelial SIRT6 is vital to prevent hypertension and associated cardiorenal injury through targeting Nkx3.2-GATA5 signaling. Circ. Res. 2019, 124, 1448–1461. [CrossRef] [PubMed]
97. Epstein, J.A.; Buck, C.A. Transcriptional regulation of cardiac development: Implications for congenital heart disease and DiGeorge syndrome. Pediatr. Res. 2000, 48, 717–724. [CrossRef] [PubMed]
98. Wilson, D.J.; Britton, S.B.; McKeown, C.; Kelly, D.; Cross, I.E.; Strobel, S.; Scambler, P.J. Noonan’s and DiGeorge syndromes with monosomy 22q11. Arch. Dis. Child. 1993, 68, 187–189. [CrossRef] [PubMed]
99. Guo, J.; Wang, Z.; Wu, J.; Liu, M.; Li, M.; Sun, Y.; Huang, W.; Li, Y.; Zhang, Y.; Tang, W.; et al. Endothelial SIRT6 is vital to prevent hypertension and associated cardiorenal injury through targeting Nkx3.2-GATA5 signaling. Circ. Res. 2019, 124, 1448–1461. [CrossRef] [PubMed]
100. Lough, J.; Sugi, Y. Endoderm and heart development. Dev. Dyn. 2000, 217, 327–342. [CrossRef] [PubMed]
110. Foley, A.C.; Mercola, M. Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. Genes Dev. 2005, 19, 387–396. [CrossRef]

111. Foley, A.C.; Gupta, R.W.; Guzzo, R.M.; Korol, O.; Mercola, M. Embryonic heart induction. Ann. N. Y. Acad. Sci. 2006, 1080, 85–96. [CrossRef] [PubMed]

112. Fujiwara, J.; Yamato, E.; Yonemura, S.; Hosoda, K.; Masui, S.; Nakao, K.; Miyazaki, J.; Niwa, H. Differentiation of embryonic stem cells is induced by GATA factors. Genes Dev. 2002, 16, 784–789. [CrossRef] [PubMed]

113. Afouda, B.A.; Ciu-CNuli, A.; Patient, R. GATA4, 5 and 6 mediate TGFbeta maintenance of endodermal gene expression in Xenopus embryos. Development 2005, 132, 763–774. [CrossRef] [PubMed]

114. Liu, Y.; Asakura, M.; Inoue, H.; Nakamura, T.; Sano, M.; Niou, Z.; Chen, M.; Schwartz, R.J.; Schneider, M.D. Sox17 is essential for the specification of cardiac mesoderm in mouse embryos. Proc. Natl. Acad. Sci. USA 2007, 104, 3859–3864. [CrossRef] [PubMed]

115. Takeuchi, J.K.; Bruneau, B.G. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Dev. Biol. 2007, 303, 57–65. [CrossRef]

116. Zhou, L.; Liu, Y.; Lu, X.; Dixon, R.A. Cardiac gene activation analysis in mammalian non-myoblastic cells by Nkx2-5, Tbx5, and Gata4 and Myocd. PLoS ONE 2012, 7, e48028. [CrossRef]

117. Christoforou, N.; Chellappan, M.; Adler, A.F.; Kirkton, R.D.; Wu, T.; Addis, R.C.; Bursac, N.; Leong, K.W. Transcription factors MYOCD, SRF, Mesp1 and SMARCD3 enhance the cardio-inducing effect of GATA4, Tbx5, and MEF2C during direct cellular reprogramming. PLoS ONE 2013, 8, e63577. [CrossRef]

118. Fu, J.D.; Stone, N.R.; Liu, L.; Spencer, C.I.; Qian, L.; Hayashi, Y.; Delgado-Olguin, P.; Ding, S.; Bruneau, B.G.; Srivastava, D. Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Res. 2013, 1, 235–247. [CrossRef]

119. Wang, L.; Liu, Z.; Yin, C.; Asfour, H.; Chen, O.; Lu, X.; Dixon, R.A. Critical factors for cardiac reprogramming of fibroblasts to cardiomyocyte-like cells. J. Mol. Cell Cardiol. 2012, 53, 323–332. [CrossRef]

120. Srivastava, D.; Ieda, M.; Fu, J.D.; Delgado-Olguin, P.; Vedantham, V.; Hayashi, Y.; Bruneau, B.G.; Srivastava, D. Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Cell. 2010, 142, 375–386. [CrossRef] [PubMed]

121. Song, K.; Nam, Y.J.; Luo, X.; Qi, X.; Tan, W.; Huang, G.N.; Acharya, A.; Smith, C.L.; Talquist, M.D.; Neilson, E.G.; et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485, 599–604. [CrossRef] [PubMed]

122. Jayawardena, T.M.; Egemnazarov, B.; Finch, E.A.; Zhang, L.; Luo, X.; Qi, X.; Tan, W.; Huang, G.N.; Acharya, A.; Smith, C.L.; Talquist, M.D.; Neilson, E.G.; et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485, 599–604. [CrossRef] [PubMed]

123. Gallagher, J.M.; Komati, H.; Roy, E.; Nemer, M.; Latinkic, B.V.; Dissociation of cardiogenic and postnatal myocardial activities of Gata4 and Myocd. Stem Cell Rep. 2013, 8, 102379. [CrossRef] [PubMed]

124. Garnatz, A.S.; Gao, Z.; Broman, M.; Martens, S.; Earley, J.U.; Svensson, E.C. FOG-2 mediated recruitment of the NuRD complex regulates cardiomyocyte proliferation during heart development. Dev. Biol. 2014, 395, 50–61. [CrossRef]

125. Zhang, W.; Shen, L.; Deng, Z.; Ding, Y.; Mo, X.; Xu, Z.; Gao, Q.; Yi, L. Novel missense variants of ZFPM2/FOG2 identified in congenital heart defect patients with cardiac malformations. Genes Dev. 2014, 28, 95253. [CrossRef] [PubMed]

126. Carter, D.R.; Buckle, A.D.; Tanaka, K.; Perdomo, J.; Chong, B.H. Art27 interacts with GATA4, FOG2 and NKX2.5 and is a novel co-repressor of cardiac genes. Genes Dev. 2014, 28, 95253. [CrossRef] [PubMed]

127. Gallagher, J.M.; Yamak, A.; Kirilenco, P.; Black, S.; Bochter, M.; Lefebvre, C.; Nemer, M.; Latinkic, B.V. Carboxyl terminus of GATA4 transcription factor is required for its cardiogenic activity and interaction with CDK4. Mech. Dev. 2014, 134, 31–41. [CrossRef] [PubMed]

128. Gallagher, J.M.; Yamak, A.; Kirilenco, P.; Black, S.; Bochter, M.; Lefebvre, C.; Nemer, M.; Latinkic, B.V. Carboxyl terminus of GATA4 transcription factor is required for its cardiogenic activity and interaction with CDK4. Mech. Dev. 2014, 134, 31–41. [CrossRef] [PubMed]

129. Garnatz, A.S.; Gao, Z.; Broman, M.; Martens, S.; Earley, J.U.; Svensson, E.C. FOG-2 mediated recruitment of the NuRD complex regulates cardiomyocyte proliferation during heart development. Dev. Biol. 2014, 395, 50–61. [CrossRef]

130. Gallagher, J.M.; Yamak, A.; Kirilenco, P.; Black, S.; Bochter, M.; Lefebvre, C.; Nemer, M.; Latinkic, B.V. Carboxyl terminus of GATA4 transcription factor is required for its cardiogenic activity and interaction with CDK4. Mech. Dev. 2014, 134, 31–41. [CrossRef] [PubMed]

131. Gallagher, J.M.; Yamak, A.; Kirilenco, P.; Black, S.; Bochter, M.; Lefebvre, C.; Nemer, M.; Latinkic, B.V. Carboxyl terminus of GATA4 transcription factor is required for its cardiogenic activity and interaction with CDK4. Mech. Dev. 2014, 134, 31–41. [CrossRef] [PubMed]
136. Ma, C.X.; Song, Y.L.; Xiao, L.; Xue, L.X.; Li, W.J.; Laforest, B.; Komati, H.; Wang, W.P.; Jia, Z.Q.; Zhou, C.Y.; et al. EGF is required for cardiac differentiation of P19CL6 cells through interaction with GATA-4 in a time- and dose-dependent manner. *Cell. Mol. Life Sci.* **2015**, *72*, 2005–2022. [CrossRef]

137. van Berlo, J.H.; Elrod, J.W.; Aronow, B.J.; Pu, W.T.; Molkentin, J.D. Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 12331–12336. [CrossRef]

138. Yamak, A.; Temsah, R.; Maharsy, W.; Caron, S.; Paradis, P.; Aries, A.; Nemer, M. Cyclin D2 rescues size and function of GATA4 haplo-insufficient hearts. *Am. J. Physiol. Heart Circ. Physiol.* **2012**, *303*, H1057–H1066. [CrossRef]

139. Katanasaka, Y.; Suzuki, H.; Sunagawa, Y.; Hasegawa, K.; Morimoto, T. Regulation of Cardiac Transcription Factor GATA4 by Post-Translational Modification in Cardiomyocyte Hypertrophy and Heart Failure. *Int. Heart J.* **2016**, *57*, 672–675. [CrossRef]

140. Xu, Y.; Liang, C.; Luo, Y.; Xing, W.; Zhang, T. Possible mechanism of GATA4 inhibiting myocardin activity during cardiac hypertrophy. *J. Cell Biochem.* **2019**, *120*, 9047–9055. [CrossRef]

141. Zhou, P.; He, A.; Pu, W.T. Regulation of GATA4 transcriptional activity in cardiovascular development and disease. *Curr. Top. Dev. Biol.* **2012**, *100*, 143–169. [CrossRef] [PubMed]

142. Walsh, E.P.; Cecchin, F. Arrhythmias in adult patients with congenital heart disease. *Circulation* **2007**, *115*, 534–545. [CrossRef] [PubMed]

143. Schlesinger, J.; Schueler, M.; Grunert, M.; Fischer, J.J.; Zhang, Q.; Krueger, T.; Lange, M.; Tonjes, M.; Dunkel, I.; Sperling, S.R. The cardiac transcription network modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modifications, and microRNAs. *PLoS Genet.* **2011**, *7*, e1001313. [CrossRef] [PubMed]

144. He, A.; Gu, F.; Hu, Y.; Ma, Q.; Ye, L.Y.; Akiyama, J.A.; Visel, A.; Pennacchio, L.A.; Pu, W.T. Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease. *Nat. Commun.* **2014**, *5*, 4907. [CrossRef] [PubMed]

145. Zhang, C.; Basta, T.; Klymkowsky, M.W. SOX7 and SOX18 are essential for cardiogenesis in Xenopus. *Dev. Dyn.* **2005**, *234*, 878–891. [CrossRef] [PubMed]